Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886763 | 0.94 | SMN1; SMN2 (0.42) | ENPP2P2RX3SMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL5887405 | 0.92 | SMN1; SMN2 (0.42) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5886867 | 0.92 | BRAF (0.48) | CYP2C19KMT2ABRAFCTNNB1TCF7L2 | |
| SCHEMBL5887410 | 0.92 | SMN1; SMN2 (0.46) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5886889 | 0.91 | MAPK10 (0.45) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5886918 | 0.91 | CTNNB1 (0.43) | SMN1; SMN2MEN1CYP2C19KMT2ABRAF | |
| SCHEMBL5887306 | 0.91 | ME2 (0.42) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5887394 | 0.90 | ACHE (0.44) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5887146 | 0.90 | CTNNB1 (0.43) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A | |
| SCHEMBL5887428 | 0.90 | SMN1; SMN2 (0.42) | ENPP2SMN1; SMN2MEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | ENPP2 3051/4885P2RX3 922/4885SMN1; SMN2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.